PAI HOLDINGS
SpecialtyPAI HOLDINGS is a specialty pharmaceutical company focused on Dermatology, Neurology, Infectious Disease.
PAI HOLDINGS's Key Drugs
PAI HOLDINGS's core commercial portfolio centers on SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, spanning Dermatology and Neurology — its most strategically important drugs approved in the last 15 years.
PAI HOLDINGS's Recent FDA Approvals
New NDA/BLA approvals for PAI HOLDINGS over the last two years — novel drugs only, excluding generics and label supplements.
PAI HOLDINGS's Therapeutic Areas
PAI HOLDINGS's approved drugs and pipeline span 5 therapeutic areas, led by Dermatology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PAI HOLDINGS's Top Competitors
PAI HOLDINGS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PAI HOLDINGS Pipeline Snapshot
Active clinical trials for PAI HOLDINGS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 1951-05-03
- Latest
- 2026-06-18
- Applications
- 52